PF 6473871

Drug Profile

PF 6473871

Alternative Names: EXC-001; PF-06473871; PF-6473871

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Excaliard Pharmaceuticals; Isis Pharmaceuticals
  • Developer Pfizer
  • Class Antisense oligonucleotides
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Scars

Most Recent Events

  • 28 Jul 2015 Discontinued - Phase-II for Scars in USA, Germany, Netherlands, Spain, Hungary (Intradermal)
  • 08 Sep 2014 Pfizer completes enrolment in its phase II trial for Scars in USA, Germany, Hungary, Netherlands & Spain (NCT01730339)
  • 05 Sep 2014 Pfizer plans a phase II extension trial for Scars in USA (NCT02205476)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top